Orai3 is a predictive marker of metastasis and survival in resectable lung adenocarcinoma

Nazim Benzerdjeb; Henri Sevestre; Ahmed Ahidouch; Halima Ouadid-Ahidouch

doi:10.18632/oncotarget.13149

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Orai3 is a predictive marker of metastasis and survival in resectable lung adenocarcinoma

Nazim Benzerdjeb _, Henri Sevestre, Ahmed Ahidouch and Halima Ouadid-Ahidouch

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:81588-81597. https://doi.org/10.18632/oncotarget.13149

Metrics: PDF 1990 views | HTML 1779 views | ?

Abstract

Nazim Benzerdjeb1,2, Henri Sevestre2, Ahmed Ahidouch2,3, Halima Ouadid-Ahidouch1

1Laboratory of Cellular and Molecular Physiology, LPCM: EA 4667, SFR CAP-SANTE (FED 4231), UFR of Sciences, Amiens, France

2Department of Pathology, Amiens University Hospital, Amiens, France

3Department of Biology, Ibn Zohr University, Agadir, Morocco

Correspondence to:

Halima Ouadid-Ahidouch, email: [email protected]

Nazim Benzerdjeb, email: [email protected]

Keywords: orai3, lung adenocarcinoma, prognostic marker, survival

Received: June 11, 2016 Accepted: October 17, 2016 Published: November 07, 2016

ABSTRACT

Orai3 channel has emerged as important player in malignant transformation. Indeed, its expression is increased in cancer and favors cell proliferation and survival by permitting calcium influx. In this study, Orai3 was overexpressed in lung adenocarcinoma as compared to their matched non-tumour samples and was associated with tumoural aggressiveness. Moreover, its expression was associated with estrogen receptor alpha (ERα) expression and visceral pleural invasion in multivariate analysis. Furthermore, both the overall survival (OS) median and the metastasis free survival (MFS) median of tumors with high Orai3 expression were lower than in low Orai3 expression regardless of cancer stage (35.01 months vs. 51.11 months for OS and 46.01 months vs. 62.04 months for MFS). In conclusion, Orai3 protein level constitutes an independent prognostic marker in lung adenocarcinoma, and a novel prognostic marker that could help selecting the patients with worst prognosis to be treated with adjuvant chemotherapy in resectable stage.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13149

Publication Alerts

Research Papers:

Orai3 is a predictive marker of metastasis and survival in resectable lung adenocarcinoma

Abstract